Revenue Comparison
Chart: Revenue Comparison. Values in USD_BILLIONS. In Q2 2026: Biogen 2.736, Gilead Sciences 7.803.
Biogen vs Gilead Sciences: Revenue Comparison
Biogen (BIIB) and Gilead Sciences (GILD) are peers in Healthcare. Biogen reported revenue of $2.7B as of Q2 2026, compared with $7.8B for Gilead Sciences. Gilead Sciences leads on revenue.
Biogen's gross margin is 56.9% versus 79.8% for Gilead Sciences. Biogen's net margin is 3.6% versus -134.5% for Gilead Sciences.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Biogen, Gilead Sciences.| Metric | Biogen | Gilead Sciences |
|---|---|---|
| Market Cap | - | - |
| Revenue | $2.74B | $7.80B |
| Cost of Revenue | $1.18B | $1.58B |
| Gross Profit | $1.56B | $6.22B |
| Operating Income | $318.00M | $-10.39B |
| Net Income | $98.00M | $-10.50B |
| R&D Expense | $496.00M | $1.76B |
| Earnings Per Share | $0.66 | -$8.45 |
| Gross Margin | 56.9% | 79.8% |
| Operating Margin | 11.6% | -133.2% |
| Net Profit Margin | 3.6% | -134.5% |
| Free Cash Flow | $490.00M | $3.69B |
| Cumulative Free Cash Flow | $47.88B | $155.83B |
| Operating Cash Flow | $449.00M | $3.57B |
| Cash & Equivalents | $1.28B | $3.18B |